P3 Health Partners (PIII) Q3 2026 earnings review
P3 Health Partners charges more per patient, but settlements drive its profit
P3 Health Partners, which manages care for Medicare patients for a fixed monthly fee, is charging insurers more per patient while one-off settlements still pad its profit. Third-quarter revenue rose 15% as an 18% jump in funding per patient outweighed a smaller patient base, and cash burn nearly stopped. Chief executive Aric Coffman raised the middle of the full-year profit outlook to $100 million, but because nine-month profit is already $101 million, the plan implies a slight loss in the fourth quarter by our math.
| Revenue | $396.3M +14.8% from a year ago |
|---|---|
| Per-member capitated revenue | +18% from a year ago (at-risk members -9%) |
| Adjusted EBITDA (excluding one-off settlements) | $11.9M $20.9M reported (includes $8.9M of settlements) |
| Full-year Adjusted EBITDA outlook | Raised $5M at midpoint middle of the range: $100M ($101.1M already booked in 9M) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because underlying per-patient funding and cash burn improved, while the profit outlook and capital structure still leave common shareholders with almost nothing. Even after stripping out prior-year insurer settlements, P3 earned about $12 million of operating cash profit in the third quarter, above what the company's own prior plan pointed to. The bad news: preferred stock dividends took $15 million of third-quarter profit, and the updated full-year plan implies no profit at all in the fourth quarter.
The question now is whether P3's higher per-patient funding can produce profit in the fourth quarter and in 2027 without prior-year insurer settlements. Either the repriced insurance contracts cover seasonal winter medical costs on their own, or the business falls back to breakeven once settlement credits run out. Fourth-quarter profit excluding prior-year settlements will tell.
🐂 Bull Case
Higher Funding Per Patient Carries Top-Line Growth
P3 Health Partners manages medical care for Medicare patients, taking a fixed monthly payment for each patient from insurance plans. That payment, called capitated revenue, is growing fast enough per patient to outweigh a smaller patient base. Chief executive Aric Coffman said the company carries "real momentum into 2027, as evidenced by our medical cost trend".
The healthcare group shrank its at-risk patient count by 9% from a year ago to 105,000 through "intentional network and payer rationalization". Yet revenue per at-risk member rose 18% on "improved network economics, rate progression, and burden of illness performance", lifting total revenue 14.8% to $396.3 million. Medical expense fell 19.8 percentage points of revenue as claims dropped.
- Per-member capitated revenue growth: 18% from a year ago, up from 15% in Q2 and 14% in Q1
- Medical margin excluding one-off settlements: $35.0 million ($111 per member per month), down from $52.9 million in Q2 on seasonal care use
- Lives under management service arrangements (fee-paying patients who may later convert to full risk): 28,000, unchanged from Q2
- Other revenue (care coordination and management fees): $30.1 million, up from $3.7 million a year ago
What to watch: the 2027 Medicare Advantage enrollment reset in the first quarter. If P3 keeps its patient count near 105,000 while holding these higher per-patient funding rates, revenue can grow without relying on fee spikes.
Operating Cash Burn Nearly Stopped in Q3
For the first half of 2026, P3 reported positive operating profit while burning $89.4 million of operating cash. That gap kept doubts about its ability to stay in business at the center of the story.
In the third quarter, the cash drain slowed to a trickle. Nine-month operating cash flow was negative $90.1 million, which means the third quarter used only $0.7 million of operating cash by our math. Total cash and restricted cash more than doubled from June to $45.8 million, helped by $24.3 million of net financing inflows during the quarter.
One quarter of near-breakeven cash flow does not settle the funding risk, because P3 still paid down $40.3 million of medical claims and $51.4 million of health plan settlements over the nine months. What to watch: fourth-quarter operating cash flow and the going-concern note in the annual report. A positive cash quarter without new preferred stock sales would show the business can fund itself.
🐻 Bear Case
One-Off Settlements Still Drive the Profit Outlook
P3 raised the bottom of its full-year Adjusted EBITDA outlook (operating profit before interest, taxes, depreciation and one-off items) by $10 million, putting the middle of the range at $100 million. Coffman pointed to "the consistency of our results", and the company credited year-to-date performance alongside "the prior-year development and payer settlements recognized in the quarter".
The numbers show that old settlements did the work. P3 booked $8.9 million of favorable payer settlements and prior-year claims development in the third quarter, lifting Adjusted EBITDA to $20.9 million ($11.9 million without them, by our math). Across the first nine months, Adjusted EBITDA already totals $101.1 million, and $71.4 million of that—or 71% by our math—came from prior-period settlements.
Because nine-month profit is already $101.1 million, a $100 million full-year midpoint implies negative $1.1 million of Adjusted EBITDA for the fourth quarter by our math. That cuts against the claim of steady momentum. What to watch: fourth-quarter Adjusted EBITDA excluding prior-year items. A loss in the fourth quarter would show that seasonal winter medical costs still wipe out P3's underlying profit.
Preferred Stock and Maturing Debt Squeeze Common Shareholders
Earlier this year, P3's backing sponsor exchanged debt for preferred stock and provided fresh financing to fix the balance sheet. While that rescue kept P3's payer contracts intact and lifted stockholders' equity to $110.5 million, the cost of that capital is now taking almost all of the profit.
In the third quarter, P3 earned $30.8 million in total net income, and $15.6 million belonged to the controlling company after partner shares. Cumulative preferred stock dividends—which pay 13.5% to 19.5%—took $15.2 million of that, up from $9.6 million in the second quarter. That left just $0.45 million, or $0.07 per diluted share, for Class A common shareholders.
- Preferred stock on the balance sheet: $185.2 million across five series
- Diluted common share count: 6.63 million, more than double the 3.27 million a year ago
- Debt due within one year: $84.5 million, up from $22.2 million in Q2 as term debt moved into the current window
What to watch: how P3 refinances the $84.4 million current portion of long-term debt before next September. Another round of high-dividend preferred stock or warrants would leave even less for common shareholders.
Risks this quarter didn't answer
Because the supplied materials include only the earnings release and financial tables, four standing risks await the conference call or the quarterly 10-Q filing.
- At-risk membership and 2027 plan exits: membership stayed at 105,000 (down 9% from a year ago), and management had promised a clear picture of 2027 insurer county exits on the Q3 call.
- Related-party settlements and fees: the release does not say how much of Q3's $8.9 million settlement benefit came from Atrio (an insurer backed by P3's sponsor) or how much G&A went to related-party Allymar; Note 14 of the 10-Q will show both.
- Insurer concentration: four health plans made up 61% of revenue in Q2; the 10-Q concentration table will show whether that dependence grew.
- Nebraska full-risk conversion: P3 still manages 28,000 service lives, but the performance targets required to convert them to full capitation in 2028 remain undisclosed.
💲 Other KPIs
Money owed to P3 by health insurers held near June's $135.3 million level, but remains up 45.3% from $92.5 million at the end of 2025. That build tied up $27.6 million of cash over the first nine months, showing that P3 has not yet collected all of its booked revenue and settlement gains in cash.
Overhead costs rose 53.1% from a year ago and climbed from $32.4 million in the second quarter. As a share of revenue, the line moved up 2.2 percentage points from a year ago to 8.6%. Excluding stock compensation and minor items, adjusted operating expense rose from $21.1 million a year ago to $34.6 million.
A premium deficiency reserve is a liability P3 sets aside on its balance sheet for insurance contracts it expects to lose money on. The reserve dropped from $72.7 million in June and $86.1 million in December. Releasing $28.0 million of that reserve reduced operating expenses and lifted GAAP operating income this quarter, though P3 strips the benefit out of Adjusted EBITDA.
🔮 Guidance
Raised. P3 lifted the bottom of its full-year sales range by $25 million, putting the middle of the range at $1,562.5 million, or 7.1% growth. By our math, that leaves $393.4 million for the fourth quarter—up just 2.2% from a year ago, down from 14.8% growth in Q3. Earlier in the year, the healthcare company had trimmed the midpoint twice before this increase: -$25M, -$25M, +$12.5M.
Raised. Management lifted the low end by $10 million, moving the middle of the range up $5 million to $100 million. Because nine-month Adjusted EBITDA is already $101.1 million, the middle of the plan leaves negative $1.1 million for the fourth quarter by our math, and even the top of the range implies just $8.9 million. It is the third raise this year, and the smallest: +$30M, +$55M, +$5M.
Unchanged. The outlook still calls for $280 million at the middle of the range, up from $23.5 million in 2025. With $215.4 million booked through September, the middle of the range leaves $64.6 million for the fourth quarter by our math—up from $43.9 million in Q3, even though Q4 typically brings heavier winter medical claims. Prior midpoint moves this year were +$30M, +$70M, $0M.
Unchanged. The middle of the range stays at $225 per member per month, matching the $226 per member per month P3 earned across the first nine months. Hitting the middle of the range requires fourth-quarter per-member margins to rebound from Q3's $140 back toward the full-year average.
Unchanged. The plan still points to 104,000 members at the middle of the range, down 10.3% from the end of 2025. Since P3 ended September with about 105,000 at-risk members, the middle of the range implies a drop of roughly 1,000 members in the fourth quarter by our math. Earlier this year, P3 cut the midpoint twice: -5,500, -2,500, 0.
❓ Key Questions
What is the 2027 membership impact from insurer county exits?
Last quarter, management promised a clearer picture of 2027 Medicare Advantage benefit designs and insurer county exits on the third-quarter call. With at-risk membership already down 9% this year, investors need to know whether January 2027 brings another step-down.
How much of Q3's $8.9 million settlement came from Atrio?
In the first half, a health plan backed by P3's controlling sponsor provided nearly half of P3's profit through prior-year claims relief. The press release does not disclose how much of Q3's $8.9 million settlement benefit came from that related party.
Why did overhead expenses jump to $34.3 million in Q3?
Corporate, general and administrative expense rose 53% from a year ago and climbed another $1.9 million from the second quarter. In Q2, fees paid to related-party Allymar drove most of the increase; management has not said whether those fees are permanent.
How will P3 refinance the $84.4 million debt due within a year?
Long-term debt due within 12 months jumped from $21.8 million in June to $84.4 million in September against $45.8 million of cash. Refinancing that balance into more 19.5% preferred stock would deepen the squeeze on common shareholders.